The frequency of metabolic syndrome in patients with schizophrenia and schizoaffective disorder;Bir grup şizofreni ve şizoaffektif bozukluk hastasinda metabolik sendrom sikliǧi

Anadolu Psikiyatri Dergisi

Volumn 10, Issue 1, 2009, Pages 26-33

  Güleç Öyekcin, Demet ^a  

^a Erzincan Devlet Hastanesi   (Turkey)

Author keywords

ATP III; Metabolic syndrome; Schizoaffective disorder; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FLUPENTIXOL; FLUPHENAZINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGE DISTRIBUTION; ARTICLE; BLOOD ANALYSIS; DISEASE DURATION; DRUG USE; FEMALE; FREQUENCY ANALYSIS; HEBEPHRENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PARANOIA; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE;

EID: 65549086678     PISSN: 13026631     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Reaven GM. Banting lecture: role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
2. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III B. Schizophr Res 2005; 80:19-32.
3. Saw SM. The epidemiology of obesity: a review. Ann Acad Med Singapore 1997; 26:489-493.
4. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, et al., InterASIA Collaborative Group. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005; 365(9468):1398-1405.
5. Thakore J, Mann J, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naïve and drug free patients with schizophrenia. Int J Obesity Relat Metab Disord 2002; 26:137-141.
6. Thakore JH, Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry 2004; 184 (S47):76-79.
7. Brugha TS, Wing JK, Smith BL. Physical health of the long-lerm mentally ill in the community: is there unmet need? Br J Psychiatry 1989; 155:777-781.
8. Kendrick T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br J Psychiatry 1996; 169:733-739.
9. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
10. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Expert panel on detection and evaluation of treatment of high blood cholesterol in adults. JAMA 2001; 285(19): 2486-2497.
11. Wirshing DA, Meyer JM. Obesity in patients with schizophrenia. JM Meyer, H Nasrallah (Eds.), Medical Illness and Schizophrenia. Washington, D.C., American Psychiatric Press, 2003, p. 39-58.
12. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001; 62(Suppl. 27):27-34.
13. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41:715-722.
14. Isomaa B, Almgren P: Tuomi T. Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689.
15. Remington G. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining? Am J Psychiatry 2006; 163:1132-1134.
16. Dixon L. Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26:903-912.
17. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27:2444-2449.
18. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002; 55:277-284.
19. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163:427-436.
20. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64:575-579.
21. Basu R, Brar JS, Chengappa KNR, John V. Parepally H, Gershon S, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004; 6:314-318.
22. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004; 49:753-760.
23. Saddichha S. Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008; 101:266-272.
24. Poulin MJ, Cortese L, Williams R, Wine N, McIntyre RS. Atypical antipsychotics in psychiatry practice: practical implications for clinical monitoring. Can J Psychiatry 2005; 50:555-562.
25. Bayram F, Gündoǧan K, Öztürk A, Yazici C. Dünyada ve Türkiye'de metabolik sendromun daǧilimi. Türkiye Klinikleri 2006; 2:18-24.
26. Cerit C, Özten E. Yildiz M. Şizofreni hastalarinda metabolik sendrom sikliǧi ve ilişkili etmenler. Türk Psikiyatri Dergisi 2008; 19:124-132.
27. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
28. Canadian Diabetes Association. 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27(Suppl. 2):10-13.
29. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(Suppl. I):1-93.
30. Osby U. Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res 2000; 45:21-8.
31. Brown S. Excess mortality of schizophrenia, a meta-analysis. Br J Psychiatry 1997; 171:502-508.
32. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51:492-501.
33. Correll C, Frederickson AM, Kane JM, Manu P. Does antipsycholic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89:91-100.